Reduced susceptibility to aztreonam-avibactam conferred by acquired AmpC-type β-lactamases in PBP3-modified Escherichia coli.
Nicolas HelsensMustafa SadekChristophe Le TerrierLaurent PoirelPatrice NordmannPublished in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2024)
Although none of the recombinant strains tested displayed clinical resistance to aztreonam-avibactam, our data emphasize that the occurrence of such profile might be of clinical relevance for MBL-producing strains.